机构：[1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China[2]RadiationOncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technologyof China, Chengdu, China四川省肿瘤医院[3]Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences,Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan,China四川省人民医院[4]Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study,Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan,China四川省人民医院
Background As a novel pillar for lung adenocarcinoma (LUAD) treatment, immunotherapy has limited efficiency in LUAD patients. The nucleic acid sensing (NAS) pathways are critical in the anti-tumor immune response, but their role in LUAD remains controversial.Objective The study aims to develop a classification system to identify immune subtypes of LUAD based on nucleic acid sensing-related genes so that it can help screen patients who may respond to immunotherapy.Methods We performed a comprehensive bioinformatics analysis of the NAS molecule expression profiles across multiple public datasets. Using qRT-PCR to verify the NAS genes in multiple lung cancer cell lines. Molecular docking was performed to screen drug candidates.Results The NAS-activated subgroup and NAS-suppressed subgroup were validated based on the different patterns of gene expression and pathways enrichment. The NAS-activated subgroup displayed a stronger immune infiltration and better prognosis of patients. Moreover, we constructed a seven nucleic acid sensing-related risk score (NASRS) model for the convenience of clinical application. The predictive values of NASRS in prognosis and immunotherapy were subsequently fully validated in the lung adenocarcinoma dataset and the uroepithelial carcinoma dataset. Additionally, five potential drugs binding to the core target of the NAS signature were predicted through molecular docking.Conclusion We found a significant correlation between nucleic acid sensing function and the immune treatment efficiency in LUAD. The NASRS can be used as a robust biomarker for the predicting of prognosis and immunotherapy efficiency and may help in clinical decisions for LUAD patients.
基金：
Department of Science and Technology of Sichuan Province [2020YJ0446]; Excellent Youth Program Fund of Sichuan Cancer Hospital [YB2021026]
第一作者机构：[1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China[2]RadiationOncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technologyof China, Chengdu, China
通讯作者：
通讯机构：[1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China[2]RadiationOncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technologyof China, Chengdu, China[*1]School of Medicine, University of Electronic Science and Technology of China, No. 4 Section 2, North Jianshe Road, Chengdu, 610054, Sichuan, China and Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
推荐引用方式(GB/T 7714)：
Peng Xinhao,Wu Hong,Zhang Biqin,et al.A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma[J].CURRENT CANCER DRUG TARGETS.2024,24(4):425-444.doi:10.2174/1568009623666230817101843.
APA：
Peng, Xinhao,Wu, Hong,Zhang, Biqin,Xu, Chuan&Lang, Jinyi.(2024).A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.CURRENT CANCER DRUG TARGETS,24,(4)
MLA：
Peng, Xinhao,et al."A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma".CURRENT CANCER DRUG TARGETS 24..4(2024):425-444
